Bellevue Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Bellevue Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27	Closed	-$1.04K	–	483
2023 Q2	$1.04K	Buy	+27	New	+$693	﹤0.01%	476

Bellevue Asset Management's KDNY Position: Q3 2023 in Review

Bellevue Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 27 shares — an estimated $1.04K sold.

Bellevue Asset Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $1.04K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Bellevue Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bellevue Asset Management sold 27 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.04K.
Bellevue Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Bellevue Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.04K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bellevue Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.